Clinical Focus

  • Diabetes and Metabolism
  • Endocrinology

Academic Appointments

Professional Education

  • Fellowship: Stanford University Endocrinology Fellowship (2022) CA
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2020)
  • Residency: Rutgers New Jersey Medical School UMDNJ Internal Medicine Residency (2020) NJ
  • Medical Education: Tehran University of Medical Sciences (2014) Iran

All Publications

  • Regression of calcinosis cutis after inkless tattoo in a patient with dermatomyositis: therapeutic potential of microneedling. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA Motlaghzadeh, Y., Tabatabai, L. S., Longo, E., Sellmeyer, D. E. 2022


    Calcinosis cutis is defined as abnormal deposition of calcium salts in the skin and subcutaneous tissues. Dystrophic calcification, the most common form of calcinosis cutis, is associated with autoimmune connective tissue diseases. This condition is associated with severe pain and can affect the patient's quality of life and lead to long-term disability. Treatment is often challenging, and there is a very limited evidence base for potential treatments of calcinosis cutis associated with systemic sclerosis and dermatomyositis. Inkless tattoo is very similar to microneedling, a minimally invasive procedure stimulating the wound-healing cascade contributing to elastin and collagen formation as well as neovascularization. This technique has not been reported as a potential therapeutic option for calcinosis cutis. Here, we present a patient with calcinosis cutis in the setting of dermatomyositis that responded dramatically to inkless tattoo application. Our results support the need for future studies of microneedling in patients with this disorder.

    View details for DOI 10.1007/s00198-022-06501-z

    View details for PubMedID 35881144

  • Skeletal Fluorosis Due to Inhalation Abuse of a Dust Cleaner Motlaghzadeh, Y., Ku, S., Sellmeyer, D. WILEY. 2022: 102
  • Rare Causes of Hypercalcemia: 2021 Update. The Journal of clinical endocrinology and metabolism Motlaghzadeh, Y., Bilezikian, J. P., Sellmeyer, D. E. 2021


    CONTEXT: Primary hyperparathyroidism and malignancy are the etiologies in 90% of cases of hypercalcemia. When these entities are not the etiology of hypercalcemia, uncommon conditions need to be considered. In 2005, Jacobs and Bilezikian published a clinical review of rare causes of hypercalcemia, focusing on mechanisms and pathophysiology. This review is an updated synopsis of rare causes of hypercalcemia, extending the observations of the original article.EVIDENCE ACQUISITION: Articles reporting rare associations between hypercalcemia and unusual conditions were identified through a comprehensive extensive PubMed-based search using the search terms "hypercalcemia" and "etiology," as well as examining the references in the identified case reports. We categorized the reports by adults vs. pediatric and further categorized the adult reports based on etiology. Some included reports lacked definitive assessment of etiology and are reported as unknown mechanism with discussion of likely etiology.EVIDENCE SYNTHESIS: There is a growing understanding of the breadth of unusual causes of hypercalcemia. When the cause of hypercalcemia is elusive, a focus on mechanism and review of prior reported cases is key to successful determination of the etiology.CONCLUSIONS: The ever-expanding reports of patients with rare and even unknown mechanisms of hypercalcemia illustrate the need for continued investigation into the complexities of human calcium metabolism.

    View details for DOI 10.1210/clinem/dgab504

    View details for PubMedID 34240162